York Trials Unit, Department of Health Sciences, University of York, Heslington, YO10 5DD, UK.
School of Health and Social Care, Teesside University, Middlesbrough, Tees Valley, TS1 3BA, UK.
Trials. 2019 Sep 18;20(1):570. doi: 10.1186/s13063-019-3631-x.
BACKGROUND: Surgeon and patient treatment preferences are important threats to the internal and external validity of surgical trials such as PROFHER, which compared surgical versus non-surgical treatment for displaced fractures of the proximal humerus in adults. We explored the treatment preferences expressed by surgeons and patients in the trial and how these impacted on patient selection, trial conduct and patient outcome. METHODS: A series of exploratory secondary analyses of the PROFHER trial data were undertaken. We reviewed the extent of surgeon and patient treatment preferences (surgery or not surgery) at screening (n = 1250) as well as prior preference (including no preference) of randomised patients (n = 250), and assessed their impact on recruitment and adherence to follow-up and rehabilitation. Changes in treatment after 2 years' follow-up were explored. Patient preference and characteristics associated with trial inclusion or treatment preference (t test, chi-squared test, Wilcoxon rank-sum test) were included as treatment interaction terms in the primary trial analysis of shoulder functioning (Oxford Shoulder Score, OSS). RESULTS: Surgeons excluded 17% of otherwise eligible patients based on lack of equipoise; these patients had less complex fractures (p < 0.001) and tended to be older (p = 0.062). Surgeons were more likely to recommend surgery for patients under 65 years of age (p = 0.059) and who had injured their right shoulder (p = 0.052). Over half of eligible patients (56%) did not consent to take part in the trial; these patients tended to be older (p = 0.022), with a preference for not surgery (74%; which was associated with older age, p = 0.039). There were no differential treatment effects (p value of interaction) for shoulder functioning (OSS) based on subgroups of patient preference (p = 0.751), age group (p = 0.264), fracture type (p = 0.954) and shoulder dominance (p = 0.850). Patients who were randomised to their preferred treatment had better follow-up rates (94 vs 84% at 2 years) and treatment adherence (90 vs 83% reported completing home exercises). Patients who were not randomised to their preferred treatment were more likely to change their treatment preference at 24 months (60 vs 26%). CONCLUSIONS: The robustness of the PROFHER trial findings was confirmed against possible bias introduced by surgeon and patient preferences. The importance of collecting preference data is highlighted. TRIAL REGISTRATION: ISRCTN50850043 . Registered on 25 March 2008.
背景:外科医生和患者的治疗偏好是对 PROFHER 等外科手术试验内部和外部有效性的重要威胁,该试验比较了成人移位性肱骨近端骨折的手术与非手术治疗。我们探讨了试验中外科医生和患者表达的治疗偏好,以及这些偏好如何影响患者选择、试验进行和患者结局。
方法:对 PROFHER 试验数据进行了一系列探索性二次分析。我们回顾了筛选时(n=1250)以及随机患者(n=250)之前的治疗偏好(包括无偏好)的程度,并评估了它们对招募和随访以及康复依从性的影响。还探讨了 2 年随访后的治疗变化。将患者偏好以及与试验纳入或治疗偏好相关的特征(t 检验、卡方检验、Wilcoxon 秩和检验)作为治疗交互项纳入主要试验的肩部功能(牛津肩部评分,OSS)分析中。
结果:外科医生根据缺乏均衡排除了 17%的其他符合条件的患者;这些患者的骨折更为简单(p<0.001),且年龄更大(p=0.062)。对于 65 岁以下的患者(p=0.059)和右肩受伤的患者(p=0.052),外科医生更倾向于推荐手术。超过一半的合格患者(56%)不同意参加试验;这些患者年龄更大(p=0.022),更倾向于不接受手术(74%;这与年龄有关,p=0.039)。基于患者偏好(p=0.751)、年龄组(p=0.264)、骨折类型(p=0.954)和肩部优势(p=0.850)的亚组,OSS 治疗效果(p 值的交互作用)没有差异。随机分配到他们首选治疗的患者具有更好的随访率(2 年时 94%比 84%)和治疗依从性(90%比 83%报告完成家庭锻炼)。未随机分配到首选治疗的患者在 24 个月时更有可能改变治疗偏好(60%比 26%)。
结论:PROFHER 试验结果的稳健性得到了确认,没有因外科医生和患者的偏好而产生可能的偏倚。强调了收集偏好数据的重要性。
试验注册:ISRCTN50850043。于 2008 年 3 月 25 日注册。
Cochrane Database Syst Rev. 2015-11-11
Cochrane Database Syst Rev. 2022-6-21
Indian J Surg Oncol. 2024-9
Medicina (Kaunas). 2022-10-19
Cochrane Database Syst Rev. 2022-6-21
Eur J Orthop Surg Traumatol. 2022-12
Clin Orthop Relat Res. 2016-2
J Bone Joint Surg Am. 2012-7-18
Clin Orthop Relat Res. 2013-1
BMC Musculoskelet Disord. 2012-6-27
N Engl J Med. 2010-7-22